ImmaticsIMTX
IMTX
About: Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
Employees: 343
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 90 [Q2] → 90 (+0) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
4% less capital invested
Capital invested by funds: $903M [Q2] → $865M (-$38.1M) [Q3]
1.87% less ownership
Funds ownership: 75.44% [Q2] → 73.57% (-1.87%) [Q3]
60% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 42
70% less call options, than puts
Call options by funds: $2.47M | Put options by funds: $8.3M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
112%
upside
Avg. target
$17
140%
upside
High target
$19
169%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Alex Stranahan 0% 1-year accuracy 0 / 1 met price target | 112%upside $15 | Buy Maintained | 19 Nov 2024 |
Piper Sandler Joseph Catanzaro 32% 1-year accuracy 10 / 31 met price target | 169%upside $19 | Overweight Initiated | 7 Oct 2024 |
Financial journalist opinion
Positive
Zacks Investment Research
1 month ago
What Makes Immatics (IMTX) a New Buy Stock
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Zacks Investment Research
1 month ago
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.35 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics
Neutral
GlobeNewsWire
1 month ago
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers
Positive
Zacks Investment Research
1 month ago
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?
Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Seeking Alpha
2 months ago
Immatics: A Promising TCR Pipeline
Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation estimates suggest a potential stock price of ~$19.26 based on conservative revenue assumptions.
Neutral
GlobeNewsWire
2 months ago
Immatics Announces Pricing of $150 Million Public Offering
H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $150 million. The offering is expected to close on October 15, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,437,500 additional shares at the public offering price, less the underwriting discount.
Negative
Benzinga
2 months ago
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
On Thursday, Immatics N.V. IMTX stock is trading lower after the company commenced an underwritten public offering of $150 million.
Neutral
GlobeNewsWire
2 months ago
Immatics Announces Proposed $150 Million Public Offering
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the commencement of an underwritten public offering of its ordinary shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Neutral
GlobeNewsWire
2 months ago
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST
Charts implemented using Lightweight Charts™